Document:

exv10w25

Exhibit 10.25

CONFIDENTIAL TREATMENT REQUESTED

License Agreement

This License Agreement (“Agreement”) is made and entered into as of November 4, 2007, by and
between Dainippon Sumitomo Pharma Co., Ltd., a corporation having its registered office at 6-8,
Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan (“DSP”), and Alimera Sciences, Inc., a
corporation having its registered office at 6120 Windward Parkway, Suite 290, Alpharetta, GA 30005,
USA (“Alimera”), to confirm the mutual agreement of the parties with respect to certain patent
rights as set forth below.

DSP owns the patents listed in Exhibit A attached hereto and incorporated herein by this reference
(the “Patent Rights”) in the USA and other countries, jointly with a third party (the “Joint
Owner”), and pursuant to the agreement between DSP and the Joint Owner, DSP is entitled to exercise
and license the Patent Rights on an exclusive basis.

Alimera has been developing an ophthalmic product, as described in Exhibit B attached hereto and
incorporated herein by this reference (the “Licensed Product”), for treatment of diabetic macular
edema, and desires to develop and market the Licensed Product without risk of infringement action
on the Patent Rights.

Alimera proposed, and DSP accepted, that DSP would grant Alimera a license and option on the Patent
Rights.

DSP and Alimera hereby agree as follows:

	1)	 	DSP hereby grants Alimera a worldwide, fully paid up, royalty free, non-exclusive and
transferable license, with the right to sublicense, under the Patent Rights to research,
develop, manufacture, make, have made, use, market, offer to sell, sell, import and otherwise
exploit Licensed Product in the field of ophthalmology (the “Initial License”), provided that
(i) Alimera shall not grant any sublicense under, nor transfer, the Initial License without
giving a prior written notice to DSP, (ii) Alimera may grant a sublicense under, or transfer,
the Initial License to an entity if and to the extent Alimera grants such entity the right to
research, develop, manufacture, make, have made, use, market, offer to sell, sell, import or

License Agreement

1

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	otherwise exploit the Licensed Product, and (iii) DSP shall have no obligation to disclose or
provide any information on its technology and/or know-how on manufacturing of [*] to Alimera,
other than the information already disclosed by DSP to Alimera under the Non-Disclosure
Agreement dated September 13, 2006 (the “Non-Disclosure Agreement”), until the Expanded
License (as defined in Paragraph 3) below) is granted by DSP to Alimera under Paragraph 3).
	 
	2)	 	Nothing herein shall be construed as an admission by Alimera, whether direct or indirect,
immediate or remote: a) that there has been direct or contributory infringement of, or
inducement to infringe, the Patent Rights, or b) that the Patent Rights are valid or
enforceable.
	 
	3)	 	In addition, DSP hereby grants to Alimera, and Alimera hereby accepts, an option (the
“Option”) to be granted a worldwide, non-exclusive and transferable license, with the right to
sublicense, under the Patent Rights and DSP’s relevant know-how to research, develop,
manufacture, make, have made, use, market, offer to sell, sell, import and otherwise exploit
any invention covered by the Patent Rights and DSP’s relevant know-how in the field of
ophthalmology (the “Expanded License”). Alimera may exercise the Option at any time during
the period of this Agreement by giving a written notice to DSP, provided that both parties
shall discuss in good faith the terms and conditions of the Expanded License and a separate
license agreement containing agreed upon terms and conditions shall be concluded between the
parties.
	 
	4)	 	In full consideration of DSP’s agreement set forth in Paragraph 1) above and DSP’s grant of
the Option set forth in Paragraph 3) above, Alimera shall pay four hundred thousand United
States Dollars (US$400,000) to DSP in two installments as set forth below. Alimera shall,
within [*] days after each of (i) the execution of this Agreement and (ii) first regulatory
approval for the Licensed Product in the USA by the U.S. Food and Drug Administration
authorizing the marketing and sale of the Licensed Product in the USA, make a payment in the
amount of two hundred thousand United States Dollars (US$200,000) to DSP. The payments shall
be non-refundable and shall be made in United States Dollars by telegraphic transfer to the bank account

 

			
	*	 	Certain information has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

License Agreement

2

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	designated by DSP in writing. It is understood that the payments do not include any
consideration to DSP for the Expanded License. In case Alimera fails to make any of the
payments required hereunder by the due date, DSP will charge Alimera overdue interest at the
lower of (i) interest accruing on any such unpaid balance at the average year-to-date rate
London Inter-Bank Offering Rate (LIBOR) in effect from time to time plus [*] percent ([*]) per
annum or (ii) the highest rate allowable under applicable law.
	 
	5)	 	Alimera and DSP agree that all amounts payable under this Agreement shall be treated as
“royalties” within the meaning of Article 12 of the Convention between the Government of the
United States of America and the Government of Japan for the Avoidance of Double Taxation and
the Prevention of Fiscal Evasion with Respect to Taxes on Income (the “Treaty”).
Any taxes imposed on DSP and required to be paid or withheld on account of amounts
payable to DSP under this Agreement, if any, shall be deducted at the rates specified by
applicable law from the amount due hereunder. Alimera shall provide DSP with documentation
necessary to receive benefits of a tax treaty, if any. In addition, Alimera shall provide
promptly to DSP receipts from the relevant government taxing authority evidencing payment of
such tax. DSP hereby represents that (a) it is a resident of Japan within the meaning of
Article 4 of the Treaty, (b) it is entitled to claim benefits under the Treaty, and (c) the
amounts payable under this Agreement are not attributable to a permanent establishment of DSP
in the United States of America within the meaning of Article 12(3) of the Treaty. DSP will
deliver to Alimera without unreasonable delay after the signing of this Agreement a duly
completed and signed Internal Revenue Service Form W-8BEN (attached hereto as Exhibit C)
claiming a zero percent (0%) withholding rate under Article 12 of the Treaty on the amounts
payable under this Agreement.
	 
	6)	 	DSP warrants that a) it has the exclusive right to enter into this Agreement, including
the grant of the releases, license and option herein; b) there are no liens, conveyances,
mortgages, assignments, encumbrances or other agreements or obligations that would prevent or
impair the full and complete privileges granted pursuant to the full terms and conditions of
this

 

			
	*	 	Certain information has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

License Agreement

3

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	Agreement and c) it has not entered into, and shall not enter into, any other agreements that
would interfere with the rights and immunities granted herein by DSP.
	 
	 	 	EXCEPT AS OTHERWISE PROVIDED HEREIN OR, IF APPLICABLE, IN THE SEPARATE LICENSE AGREEMENT FOR
THE EXPANDED LICENSE, DSP MAKES NO REPRESENTATIONS OR
WARRANTIES, EITHER EXPRESS OR IMPLIED,
AS TO THE PATENT RIGHTS (INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE) OR THAT RESEARCH, DEVELOPMENT, MANUFACTURE, MARKETING,
DISTRIBUTION, USE OR SALE OF THE LICENSED PRODUCT AND ANY OTHER PRODUCTS WILL NOT INFRINGE
ANY PATENT RIGHTS, COPYRIGHT OR OTHER RIGHT OF ANY THIRD PARTY, OF ANY KIND OR NATURE
WHATSOEVER.
	 
	7)	 	DSP shall indemnify, defend and hold Alimera and any sublicensees and transferees of
Alimera (the “Indemnified Parties”) harmless from and against any and all liabilities,
damages, losses and costs and expenses, including, without limitation, reasonable attorneys’
fees and costs, which the Indemnified Parties may incur as a result of third party claims,
demands, actions, suits or proceedings that arise from or relate to a breach by DSP of its
representations and warranties hereunder. Alimera shall indemnify, defend and hold DSP
harmless from and against any and all liabilities, damages, losses and costs and expenses,
including, without limitation, reasonable attorneys’ fees and costs, which DSP may incur as a
result of third party claims, demands, actions, suits or proceedings that arise from or
relate to Alimera’s research, development, manufacturing, marketing, distribution, use and/or
sale of the Licensed Product, including, without limitation, any liabilities, losses or
damages whatsoever with respect to death or injury to any individual or damage to any
tangible property arising from the possession, use or operation of the Licensed Product by
Alimera or any third party in any manner whatsoever, or with respect to any injury or damage
caused by any product defect or negligence relating to the manufacture of the Licensed
Product. The indemnifying party’s obligations hereunder are conditioned on a) the party
seeking indemnification providing prompt written notice thereof and reasonable

License Agreement

4

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	cooperation, information, and assistance in connection therewith and b) it having sole control and
authority to defend, settle or compromise such claim, provided that any settlement of a claim
that does not contain an unconditional release of the party seeking indemnification will
require the prior written consent of such party. The indemnifying party shall not be
responsible for any settlement it does not approve in writing.
	 
	8)	 	This Agreement takes effect on the date first set forth above and shall continue in effect on
a country-by-country basis until the expiration of the last to expire patent in each country.
	 
	9)	 	In the event that either party materially fails to fulfill or breaches the terms and
conditions hereof, the other party shall give the defaulting party a written notice to remedy
such material failure or breach within [*] ([*]) days. In case such material failure or
breach is not remedied by the defaulting party within [*] ([*]) days after receipt of such
notice, the complaining party may terminate this Agreement at its option upon written notice
to the defaulting party. For the sake of clarity, in the case of Alimera as the defaulting
party, this Paragraph shall apply only to Alimera’s material failure to fulfill, or Alimera’s
material breach of, (a) its obligations under Paragraph 1) (i) and (ii) of this Agreement, (b)
its payment obligations under Paragraph 4) of this Agreement, and (c) its obligations under
the Non-Disclosure Agreement.
	 
	10)	 	In the event that Alimera contests the validity of the Patent Rights by itself or through any
of its affiliates or any third party, DSP may at its discretion terminate this Agreement upon
written notice to Alimera. For the purpose of this Paragraph 10), “affiliate” means an entity
organized under the laws of a jurisdiction that controls, is controlled by or is under common
control with Alimera for so long as such control exists. For the purpose of this Paragraph
10), “control” means the decision-making authority as to such entity, through ownership of
equity, membership interests or contract.
	 
	11)	 	In the event of termination of this Agreement by DSP pursuant to Paragraph 9) or 10)
above, the payments in Paragraph 2) which have not been made at the time of the termination
shall become due and payable

 

			
	*	 	Certain information has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

License Agreement

5

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	immediately upon the termination.
	 
	12)	 	Each party shall maintain in confidence, and shall not disclose to any third party, the
existence and any terms and conditions of this Agreement (“Information”), except that each
party may disclose the Information;

	 	a)	 	to its existing and prospective investors,
	 
	 	b)	 	as required by a legally enforceable order or direction or other applicable law or
regulation or to enforce this Agreement,
	 
	 	c)	 	to the Internal Revenue Service or foreign equivalent,
	 
	 	d)	 	to its attorneys, accountants or financial advisors,
	 
	 	e)	 	as needed in any filings required by the United States Securities and Exchange
Commission, other governmental authority or securities exchange,
	 
	 	f)	 	to the extent the existence or any terms and conditions of this Agreement become
publicly known without breach of this Agreement or
	 
	 	g)	 	as approved in writing by the other party (such approval not to be unreasonably
withheld);

	 	 	provided that the Information may be disclosed, i) to those who have such obligations of
confidentiality substantially similar to those provided for herein in the event of a) and d)
above, and ii) subject to a reasonable prior written notice to the other party in the event of
b), c) and e) above.
	 
	 	 	In addition, Alimera may disclose the Information to a prospective sublicensee, development
and/or commercialization partner or acquirer, and DSP may disclose the Information to the Joint
Owner and the company acting for and on behalf of the Joint Owner, provided that in each case,
the Information may be disclosed to those who have such obligations of confidentiality
substantially similar to those as provided for herein.
	 
	13)	 	This Agreement may not be amended, changed or modified, or a provision thereof waived, except
in a writing duly executed by both parties. If any provision of this Agreement is held to be
invalid, illegal or unenforceable in any respect, that provision shall be limited or
eliminated to the minimum extent necessary so that this Agreement otherwise remains in full
force and effect and enforceable.
	 
	14)	 	There are no representations, warranties, agreements or understandings

License Agreement

6

 

CONFIDENTIAL TREATMENT REQUESTED

	 	 	between the parties with respect to the subject matter of this Agreement other than as
specifically set forth in this Agreement. This Agreement states the entire agreement between
the parties with respect to the subject matter hereof, and, except for the Non-Disclosure
Agreement, supersedes all previous and contemporaneous agreements and understandings, if any,
whether written or oral, between the parties with respect to the subject matter of this
Agreement.
	 
	15)	 	The validity, construction, and performance of this Agreement shall be governed by laws of
the State of New York, United States of America, without regard for the choice of law
principles. Any difference or dispute between the parties arising out of or relating to this
Agreement or any breach thereof shall be finally settled by arbitration held in the English
language in New York City, the State of New York, United States of America in accordance with
the Rules of Arbitration of the International Chamber of Commerce. The award of the
arbitration shall be final and binding upon the parties hereto. Judgment upon such award may
be entered in any court having jurisdiction thereof. This provision shall not preclude either
party from seeking injunction or other equitable relief from a court of competent
jurisdiction.
	 
	16)	 	This Agreement may be executed in one or more counterparts, each of which is an original, but
taken together constituting one and the same instrument. Execution of a facsimile copy shall
have the same force and effect as execution of an original, and a facsimile signature shall be
deemed an original and valid signature.

License Agreement

7

 

CONFIDENTIAL TREATMENT REQUESTED

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives, as of the date first set forth above.

	 	 	 	 	 	 	 	 	 

	Dainippon Sumitomo Pharma Co., Ltd.	 	Alimera Sciences, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Kenjiro Miyatake
 

Kenjiro Miyatake
	 	By:
	 	/s/ Richard S. Eiswirth, Jr.
 

Richard S. Eiswirth, Jr.
	 	 
	 

	 	President
	 	 	 	CFO	 	 
	 
	 	 	 	 	 	 	 	 
	Date November 1, 2007	 	Date November 4, 2007	 	 

License Agreement

8

 

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT A

Patent Rights

	 	 	 	 	 

	Patent No.

	 	Country
	 	Registration Date
	 
	[*]
	 	 	 	 

 

			
	*	 	Certain information has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

License Agreement

9

 

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT B

Description of the Licensed Product

The Licensed Product is an injectable polymer tube implantable into an eye of a patient containing
a mixture of a polymer and fluocinolone acetonide, derivative or pharmaceutically acceptable salt
thereof, with a polyvinyl alcohol or other polymer coating or layer at each end of the tube.
Alimera currently uses the name “Medidur” in connection with Licensed Product. Alimera may use a
different name in connection with the commercial marketing and sale of Licensed Product.

License Agreement

10

 

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT C

Internal Revenue Service Form W-8BEN

License Agreement

11exv10w1

Exhibit 10.1

EMPLOYMENT AGREEMENT

     This Employment Agreement (this “Agreement”) is made and entered into as of the
12th day of April, 2010, between Franklin Savings and Loan Company, an Ohio savings and
loan association (the “Company”) and John J. Kuntz (the “Executive”).

     In consideration of the terms, covenants and conditions contained in this Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, agree as follows:

     1. Certain Definitions. Certain capitalized terms used in this Agreement shall have
the meanings given them in Paragraph 11 hereof.

     2. Employment. The Company hereby employs the Executive and the Executive hereby
accepts employment with the Company, subject to the terms and conditions contained in this
Agreement, for the period beginning on the Effective Date and ending as provided in Paragraph 4
hereof (the “Employment Period”).

     3. Services.

          (a) Titles and Duties. During the Employment Period, the Executive shall serve as
the Company’s Chairman of the Board and shall serve as the Chairman of the Board, President and
Chief Executive Officer of the Company’s holding company, First Franklin Corporation (the “Holding
Company”). As Chairman, President and Chief Executive Officer, the Executive shall have the normal
duties, responsibilities and authority of an executive serving in those positions, including full
control over and responsibility for the day to day operations of the Company, subject to the power
of the Company’s Board of Directors (the “Board”) to reasonably expand or limit such duties,
responsibilities and authority, either generally or in specific instances. Such services may from
time to time be for or relate to the Holding Company or other affiliates of the Company. The
Executive shall report directly to the Company’s Board and shall follow all reasonable and lawful
directions given to the Executive by or under the authority of the Board. The Executive shall
perform, observe and comply with all lawful rules, regulations and policies which the Company may
establish from time to time governing the conduct of its business.

          (b) Extent of Services. The Executive shall devote the Executive’s full business time
and attention (except for permitted vacation and leave periods) and shall use best efforts in the
performance of the Executive’s duties and responsibilities to the Company. During the Employment
Period, the Executive shall not provide services to or become engaged or employed by any other
person, firm or entity and shall not engage in any substantial manner in any other business or
business activity; provided, that the Executive may (i) serve on corporate, civic, community, or
charitable boards and committees and may participate in the activities of professional, civic,
community and charitable organizations, including holding elected office, and (ii) pursue and
participate in personal investments; so long as such activities do not materially interfere with
the Executive’s duties and responsibilities to the Company, as determined by the Board.

          (c) Location of Services. During the Employment Period, the Executive shall perform
the Executive’s duties and responsibilities from an office located in the greater

 

 

Cincinnati, Ohio area, and the Executive shall not be required to move the Executive’s principal place of
employment or residency to any location outside of a fifty (50) mile radius from 4750 Ashwood
Drive, Cincinnati, Ohio 45241, except for periodic reasonable business travel.

     4. Employment Period.

          (a) Initial Term. Except as hereinafter provided, the Employment Period shall begin on
April 1, 2010 (the “Effective Date”) and shall continue until March 31, 2013 (the “Initial Term”).

          (b) Extended Term. On April 1st of each year (each an “Anniversary Date”),
unless the Employment Period shall have been terminated pursuant to Paragraph 4(c) below, or unless
either the Company (by action of its Board) or the Executive shall have given the other party at
least thirty (30) days written notice prior to such Anniversary Date that the extension provision
in this sentence shall not apply, the Employment Period shall be automatically extended for one (1)
additional year (each such year an “Extension Period”).

          (c) Early Termination. Notwithstanding the provisions of Paragraphs 4(a) or (b) above:

               (i) The Employment Period shall terminate automatically in the event of the Executive’s death.

               (ii) The Company may terminate the Employment Period upon the Executive’s “Disability.”

               (iii) The Company may terminate the Employment Period “With Cause” at any time.

               (iv) The Executive may terminate the Employment Period “With Good Reason” at any time.

               (v) The Company may terminate the Employment Period “Without Cause” at any time.

               (vi) The Executive may terminate the Employment Period “Without Good Reason” at any time.

          (d) Notice of Termination. Any purported termination of the Employment Period by the
Company or by the Executive (other than by death of the Executive) under Paragraph 4(c) shall be
communicated by Notice of Termination to the other, setting forth the Effective Termination Date.

          (e) Effective Termination Date. The “Effective Termination Date” shall mean (i) in the
case of a termination under Paragraphs 4(a) or (b), the last day of the Initial Term or any

2

 

Extension Period, (ii) in the case of the Executive’s death, the date of death, and (iii) in
all other cases, the date specified in the Notice of Termination subject to the following:

               (A) If the Employment Period is terminated by the Company, the date specified in the Notice of
Termination may be on or after the date the Notice of Termination is given to the Executive;

               (B) If the Employment Period is terminated by the Executive, the date specified in the Notice
of Termination shall be not less than thirty (30) days after the date the Notice of Termination is
given to the Company; provided, however, that the Company shall not be required to permit the
Executive to continue working between his giving his Notice of Termination and his Effective
Termination Date.

          5. Compensation. In consideration for all services provided by the Executive to the
Company or its affiliates under this Agreement, during the Employment Period:

          (a) Annual Base Salary. During the Initial Term, the Company shall pay the Executive
an annual base salary of (i) Two Hundred Eighteen Thousand Dollars ($218,000) for the period from
the Effective Date through March 31, 2011, (ii) Two Hundred Forty-Three Thousand Dollars ($243,000)
for the period from April 1, 2011 through March 31, 2012, and (iii) Two Hundred Sixty-Eight
Thousand Dollars ($268,000) for the period from April 1, 2012 through March 31, 2013 (the “Annual
Base Salary”). The Executive’s Annual Base Salary for each Extension Period shall be reviewed and
determined by the Company’s Board in its discretion, based upon the Executive’s performance and the
financial condition and results of operations of the Company. The Executive’s Annual Base Salary
for each Extension Period must be communicated to the Executive in writing at least sixty (60) days
prior to the Anniversary Date immediately preceding what would be the first day of such Extension
Period. The Annual Base Salary shall be paid to the Executive on the regularly recurring pay
periods established by the Company, but not less frequently than monthly.

          (b) Taxes. All of the payments made to the Executive pursuant to this Paragraph 5
shall be subject to federal, state and local income tax withholding and other applicable taxes and
contribution amounts.

     6. Restricted Stock Option Award. On the Effective Date, the Company shall grant the
Executive a restricted stock award of Thirty-Eight Thousand (38,000) shares of the Company’s $0.01
par value common stock, pursuant to the terms and conditions of a Restricted Stock Option Award to
be entered into between the Company and the Executive on the Effective Date (the “Restricted Stock
Option Award Agreement”).

     7. Fringe Benefits. During the Employment Period, the Company shall provide the
Executive with the following fringe benefits (collectively, the “Fringe Benefits”):

          (a) General Fringe Benefits. The Executive shall be entitled to participate in any
health, medical, hospitalization, accident, life insurance, short-term and long-term disability

3

 

insurance, pension and profit sharing, deferred compensation, welfare benefit or other fringe
benefit plans, insured or self-funded, maintained by the Company or the Holding Company from time
to time for the benefit of its senior management or employees generally (collectively, the “Fringe
Benefit Plans”), unless such participation is declined by the Executive. Except as otherwise
provided in this Agreement, the timing and level of the Executive’s participation in such Fringe
Benefit Plans shall be governed by the specific terms and conditions of each such plan.

          (b) Specific Fringe Benefits. Without limiting the generality of Paragraph 7(a)
hereof, the Executive shall be entitled to the following specific Fringe Benefits:

               (i) Four (4) weeks of paid vacation per calendar year, and otherwise in accordance with the
Company’s general vacation policy.

               (ii) In the event of Disability, the Executive shall be entitled to benefits in accordance
with the terms and conditions of any disability program or insurance maintained by the Company.

          (c) Business Expenses. The Executive shall be reimbursed for all ordinary and
necessary business expenses incurred by the Executive in performing services for the Company and in
promoting the business of the Company, including without limitation, expenditures for travel,
lodging, meals and entertainment, with documentation submitted and otherwise in accordance with the
Company’s business expense reimbursement policy in effect from time to time.

     8. Rights Upon Termination of Employment Period.

          (a) General. Upon the termination of the Employment Period for any reason pursuant to
Paragraphs 4(a), (b), or (c) hereof, the Company shall: (i) pay the Executive the earned portion
of the Executive’s then current Annual Base Salary and accrued vacation and provide the Executive
with the Executive’s then current Fringe Benefits through the Effective Termination Date, and (ii)
pay or provide to the Executive any other amounts, Fringe Benefits, or rights required to be paid
or provided or which the Executive is entitled to receive under any insurance policy, Fringe
Benefit Plan, program, contract or agreement which by its terms specifically provides for
post-employment payments, benefits or rights (collectively, the “Accrued Obligations”). Except for
the Accrued Obligations and as otherwise specifically provided in Paragraphs 8(b) and (c) below,
the Executive shall not be entitled to any salary, bonus, long-term incentive compensation,
severance pay, salary continuation, Fringe Benefits, or other compensation relating to any periods
after the Effective Termination Date.

          (b) Termination Without Cause or With Good Reason. If the Employment Period is
terminated outside of a Change-in-Control Period: (i) by the Company Without Cause as provided in
Paragraph 4(c)(v) hereof, or (ii) by the Executive With Good Reason as provided in Paragraph
4(c)(iv) hereof; then the Company, at its expense, shall provide the Executive with the following
severance benefits:

4

 

               (i) The Executive’s then current Annual Base Salary, as in effect on the Effective Termination
Date, shall be continued until the end of the term of the then current Employment Period as
described in Paragraphs 4(a) and (b) hereof, paid monthly in arrears.

               (ii) For thirty-six (36) months after the Effective Termination Date, the Company shall
continue to provide medical and dental benefits to the Executive and the Executive’s dependants in
accordance with the most favorable plans, practices, programs or policies of the Company applicable
generally to other peer executives who are active employees and their dependants as in effect from
time to time thereafter; provided, however, that if the Executive becomes reemployed with another
employer and is eligible to receive medical or dental benefits under another employer provided plan
or under Medicare, the medical and dental benefits described herein shall be secondary to those
provided under such other plan during such applicable period of eligibility, provided that the
aggregate coverage of the combined benefit plans is no less favorable to the Executive, in terms of
amounts and deductibles and costs to the Executive, than the coverage required hereunder.

          (c) Change-In-Control. Notwithstanding any other provision of this Agreement, if the
Employment Period is terminated within a Change-in-Control Period: (i) by the Company Without Cause
as provided in Paragraph 4(c)(v) hereof, or (ii) by the Executive with Good Reason as provided in
Paragraph 4(c)(iv) hereof; then the Company or its successor, at its expense, shall provide the
Executive with the following severance benefits (in lieu of the severance benefits described in
Paragraph 8(b) hereof):

               (i) The Executive shall be paid an amount equal to 2.99 times the Executive’s “base amount”,
as defined in Section 280G(b)(3) and 280G(d) of the Code, in a lump sum within thirty (30) days of
the Effective Termination Date. This amount shall be reduced by the value, if any, realized by the
Executive from the acceleration of the vesting or exercisability of any stock options, restricted
stock or unit awards, or similar property rights resulting from or in connection with the
Change-in-Control.

               (ii) For thirty-six (36) months after the Effective Termination Date, the Company shall
continue to provide medical and dental benefits to the Executive and the Executive’s dependants in
accordance with the most favorable plans, practices, programs or policies of the Company applicable
generally to other peer executives who are active employees and their dependants as in effect from
time to time thereafter; provided, however, that if the Executive becomes reemployed with another
employer and is eligible to receive medical or dental benefits under another employer provided plan
or under Medicare, the medical and dental benefits described herein shall be secondary to those
provided under such other plan during such applicable period of eligibility, provided that the
aggregate coverage of the combined benefit plans is no less favorable to the Executive, in terms of
amounts and deductibles and costs to him, than the coverage required hereunder.

          (d) The Company’s obligation to provide the severance benefits described in Paragraphs 8(b)
and (c) hereof shall be specifically conditioned upon:

5

 

               (i) The Executive or his Personal Representative providing the Company or its successor with a
written general release of claims, substantially in form and substance as set forth in Exhibit A
attached hereto, and otherwise acceptable to the Company or its successor in all respects (the
“General Release”) within 30 days of the Effective Termination Date. The General Release shall not
be deemed provided to the Company or its successor unless and until all periods for revocation of
the General Release by the Executive, as provided for under applicable federal, state or local
laws, have completely expired and the General Release is fully enforceable against the Executive;
and

               (ii) The Executive complying with the covenants and restrictions contained in this Agreement
which survive the Effective Termination Date, including without limitation those contained in
Paragraph 9 hereof.

          (e) Upon the termination of the Employment Period pursuant to Paragraphs 4(a), (b), or (c)
hereof, the provisions of this Agreement which by their terms extend beyond the Effective
Termination Date (including without limitation Paragraphs 8, 9, 10, 12, 13 and 24 hereof) shall
survive in accordance with such terms. A party’s exercise of the right to terminate the Employment
Period shall not limit or abrogate the terminating party’s other rights and remedies regarding any
breach, default, act or omission giving rise to such termination right.

          (f) If the Executive becomes entitled to the severance benefits described in Paragraphs 8(b)
or (c) hereof, and subsequently dies, the Company shall continue to pay and provide the severance
benefits described in such Paragraphs to the Executive’s Personal Representative for the periods
described in such Paragraphs.

          (g) “Golden Parachute” Provision. Any payments made to the Executive pursuant to this
Agreement, or otherwise, are subject to and conditioned upon their compliance with 12 U.S.C.
Â§1828(k) and FDIC regulation 12 C.F.R. Part 359, Golden Parachute and Indemnification Payments.
In the event that payments pursuant to this Section 4, either alone or in combination with any
other compensation, would result in the imposition of a penalty tax pursuant to Sections 280G and
4999 of the Code (collectively, “Section 280G”), such payments shall be reduced to the maximum
amount that may be paid under Section 280G without resulting in the imposition of a penalty tax.
For purposes of this Section, any determination that a payment is subject to Section 280G shall be
made in writing by the principal certified public accounting firm or other professional selected by
the Company in its sole discretion. Any reduction pursuant to this Section 4(e)(ii) shall be first
applied against amounts that are not subject to Section 409A of the Code and, thereafter, shall be
applied against all remaining amounts subject to Section 409A of the Code on a pro rata basis.

     9. Non-Disclosure and Proprietary Rights.

          (a) Ownership of Confidential Information. The Executive acknowledges that all of the
“Confidential Information”, as hereinafter defined, known by, disclosed to or otherwise obtained by
the Executive is owned solely by the Company, will remain the exclusive property of the Company and
constitutes valuable trade secrets of the Company. The Executive acknowledges and agrees that the
unauthorized use or disclosure of such Confidential Information would cause

6

 

irreparable harm to the Company.

          (b) Non-Disclosure. The Executive will never, directly or indirectly, use, publish,
disclose, claim ownership of or communicate any of the Company ‘s Confidential Information, without
the prior written consent of the Company, except as may be required by law, pursuant to judicial or
governmental order or subpoena. If the Executive is required by law to disclose any Confidential
Information (by oral question, interrogatories, requests for information or documents, subpoena,
court order, civil investigation, demand or similar process), the Executive will, unless prohibited
by law, provide the Company with prompt notice of such request(s) so that the Company may seek an
appropriate protective order. In the event that such a protective order or other appropriate
remedy to prevent such disclosure is not obtained, the Executive may disclose only that portion of
the Confidential Information (and only to those persons) which is legally required and the
Executive agrees to fully cooperate with the Company, at the Company’s sole cost and expense, in
securing assurances that the disclosed Confidential Information will be accorded confidential
treatment.

          (c) Confidential Information. For purposes of this Agreement, the term “Confidential
Information” shall mean any of the Company ‘s trade secrets, customer information, procedures,
processes, marketing or business plans, financial information, and all other information or matters
of a confidential nature disclosed to or known by the Executive as a consequence or by reason of
the Executive’s positions as a director, officer, or employee of the Company, affecting or
relating to the Company ‘s business. Confidential Information shall not include information that:
(i) is or becomes generally available to the public other than as a result of a prohibited
disclosure by the Executive or persons to whom the Executive has made the

7

 

Confidential Information available; or (ii) is approved for release in writing by the Company’s
Board.

          (d) Non-Retention of Materials. The Executive agrees that upon termination of
employment with the Company, the Executive will surrender to the Company all agreements, contracts,
documents, records, manuals, correspondence, plans, notes, memoranda, notebooks, equipment, price
lists, customer lists, computer diskettes, CDs, tapes or other similar written or electronic
articles containing Confidential Information, including all copies thereof and any abstracts,
notes, or compilations prepared therefrom, which are in the Executive’s possession or control, and
that the Executive will retain no copies thereof.

     10. Special Regulatory Events. Notwithstanding Section 4 of this Agreement, the
obligations of the Company to the Executive shall be as follows in the event of the following
circumstances:

     (a) If the Executive is suspended and/or temporarily prohibited from participating in the
conduct of the Company’s affairs by a notice served under section 8(e)(3) or (g)(1) of the Federal
Deposit Insurance Act (the “FDIA”), the Company’s obligations under this Agreement shall be
suspended as of the date of service of such notice, unless stayed by appropriate proceedings. If
the charges in the notice are dismissed, the Company shall pay the Executive all or part of the
compensation withheld while the obligations in this Agreement were suspended and reinstate, in
whole or in part, any of the obligations that were suspended;

     (b) If the Executive is removed and/or permanently prohibited from participating in the
conduct of the Company’s affairs by an order issued under Section 8(e)(4) or (g)(1) of the FDIA,
all obligations of the Company under this Agreement shall terminate as of the effective date of
such order; provided, however, that vested rights of the Executive shall not be affected by such
termination;

     (c) If the Company is in default, as defined in section 3(x)(1) of the FDIA, all obligations
under this Agreement shall terminate as of the date of default; provided, however, that vested
rights of the Executive shall not be affected;

     (d) All obligations under this Agreement shall be terminated, except to the extent of a
determination that the continuation of this Agreement is necessary for the continued operation of
the Company, (i) by the Director of the OTS, or his or her designee at the time that the Federal
Deposit Insurance Corporation enters into an agreement to provide assistance to or on behalf of the
Company under the authority contained in Section 13(c) of the FDIA or (ii) by the Director of the
OTS, or his or her designee, at any time the Director of the OTS approves a supervisory merger to
resolve problems related to the operation of the Company or when the Company is determined by the
Director of the OTS to be in an unsafe or unsound condition; provided, however that no vested
rights of the Executive shall be affected by any such termination; and

          (e) The provisions of this Section 10 are governed by the requirements of 12 C.F.R. §563.39(b)
and in the event that any statements in this Section 10 are inconsistent with
12 C.F.R. §563.39(b), the provisions of 12 C.F.R. §563.39(b) shall be controlling.

8

 

     11. Definitions. For purposes of this Agreement, the following terms shall have the
following meanings:

          (a) “Code” means the Internal Revenue Code of 1986, as amended, and all regulations
promulgated thereunder.

          (b) “Disability” means that the Executive, due to a physical or mental illness, injury,
incapacity or other disability, has been unable to participate materially in the Company’s business
and to perform substantially the duties required of the Executive under this Agreement for an
aggregate total of one hundred eighty (180) days (whether consecutive or non-consecutive) during
any three hundred sixty (360) day period.

          (c) “With Cause” means a termination approved by the Company’s Board based on: (A) a breach
by the Executive of any provision of this Agreement that the Executive fails to remedy or cure
within thirty (30) days after written notice thereof by the Company to the Executive; (B) the
Executive’s personal dishonesty, incompetence, willful misconduct, breach of fiduciary duty
involving personal profit, intentional failure to perform stated duties (other than a failure
resulting from the Executive’s incapacity due to physical or mental illness), willful violation of
any law, rule or regulation (other than traffic violations or similar offenses), or willful
violation of any final cease and desist order; (C) any misconduct or illegal action by the
Executive that has or will have a material adverse effect on the business, assets, financial
condition or reputation of the Company or on the Executive’s reputation (including, without
limitation, the commission of a fraud, discriminatory conduct, or sexual harassment); (D) the
commission by the Executive of an act involving moral turpitude or dishonesty, whether or not in
connection with the Executive’s employment with the Company or (E) the Executive’s possession or
use of alcohol at work in violation of the Company’s policy or illegal drugs. “With Cause” shall
not include ordinary negligence, errors or omissions in the performance of the Executive’s duties,
or a decline or change in the Company’s revenues, profitability or business strategy.
Notwithstanding anything contained in this Agreement to the contrary, no act or omission by the
Executive after a Notice of Termination is given by the Executive shall constitute Cause for
purposes of this Agreement.

          (d) “With Good Reason” means a termination by the Executive based on:

               (i) a change in the Executive’s status, titles, position or responsibilities (including
reporting responsibilities) which does not reasonably represent a promotion from the Executive’s
status, titles, position or responsibilities contemplated by Paragraph 2 of this Agreement; the
assignment to the Executive of any duties which are reasonably considered inconsistent in any
material respect with the Executive’s status, titles, position, or responsibilities contemplated by
Paragraph 2 of this Agreement; or any other action by the Company which results in a significant
diminution in such status, titles, position or responsibilities, excluding for these purposes any
isolated and inadvertent action not taken in bad faith and which is remedied by the Company within
ten (10) days after receipt of notice thereof given by the Executive; or

               (ii) any material failure by the Company to comply with any of the

9

 

provisions of this Agreement, which failure is not remedied by the Company within thirty (30) days after receipt of
notice thereof given by the Executive; or

               (iii) the Executive being required to relocate the Executive’s principal place of employment
or residency in violation of Paragraph (3)(c) hereof; or

               (iv) the failure of the Company to obtain an agreement, satisfactory to the Executive, from
any successor or assign of the Company, to assume and agree to perform this Agreement, as described
in Paragraph 18 hereof, unless the Agreement would be binding upon any successor or assign by
operation of law.

Notwithstanding any other provision of this Agreement to the contrary, the voluntary termination of
the Employment Period by the Executive Without Good Reason or without the requirement of stating or
having any cause or reason during the thirty (30) day period beginning on the six month anniversary
of the effective date of a Change-in-Control event shall be deemed to be a termination by the
Executive With Good Reason for all purposes under this Agreement.

          (e) “Without Cause” means a termination of the Employment Period by the Company for any reason
other than With Cause, or the Executive’s death or Disability.

          (f) “Without Good Reason” means a termination of the Employment Period by the Executive for
any reason other than “With Good Reason”, or the Executive’s voluntary retirement, death or
Disability.

          (g) “Personal Representative” means the Executive’s executor, administrator, estate, guardian,
personal representative, attorney-in-fact, heirs or other successors-in-intent.

          (h) “Change-In-Control” means the occurrence of any of the following events: (i) the sale,
lease, exchange, transfer or other disposition of all or substantially all of the Company’s
business or assets, not made in the usual and regular course of its business; (ii) the acquisition
by any person of ownership or power to vote more than 50% of the voting stock of the Company; (iii)
the acquisition by any person of the ability to control the election of a majority of the directors
of the Company; or (iv) during any period of up to two consecutive years, individuals who at the
beginning of such period constitute the board of directors of the Company cease for any reason to
constitute at least two-thirds thereof; provided, however, that any individual whose election or
nomination for election as a member of the board of directors of the Company was approved by a vote
of at least two-thirds of the directors then in office shall be considered to have continued to be
a member of the board of directors of the Company. For purposes of this paragraph, the term
“person” refers to an individual or corporation, partnership, trust, association, or other
organization, but does not include the Company and any person or persons with whom the Company is
“acting in concert” within the meaning of 12 C.F.R. Part 574.

          (i) “Change-in-Control Period” means the period beginning on the effective date
of a Change-in-Control event and ending 12 months after the effective date of a Change-in-Control
event. Notwithstanding the foregoing, if the Employment Period is terminated by the Company prior
to the effective date of a Change-in-Control event, and if the Executive

10

 

reasonably demonstrates that such termination: (i) was at the request of a third party who has indicated an intention or
taken steps reasonably calculated to effect a Change-in-Control, or (ii) otherwise occurred in
connection with or in anticipation of a Change-in-Control, then the termination of the Employment
Period by the Company shall be deemed to have occurred within a Change-in-Control period for all
purposes under this Agreement.

     12. Indemnification. The Company shall indemnify the Executive to the fullest extent
permitted by applicable law and the Company’s articles of incorporation, constitution, charter, or
bylaws, as applicable, if the Executive is made a party or is threatened to be made a party to any
judicial, administrative or other legal proceeding because the Executive is or was a director or
officer of the Company, against liability and expenses incurred in connection with such proceeding.
The Company shall pay the Executive’s reasonable expenses, including legal fees and expenses,
incurred in connection with such proceeding in advance of the final disposition of the proceeding
on the terms and conditions of the Company’s articles of incorporation, constitution, charter, or
bylaws, as applicable,. The provisions of this Paragraph 12 shall survive the termination of the
Employment Period.

     13. No Mitigation. The Executive shall not be obligated to seek other employment or
take any other action by way of mitigation of the amounts payable to the Executive under any of the
provisions of this Agreement and such amounts shall not be reduced (except to the extent set forth
in Paragraphs 8(b)(ii) and 8(c)(ii) hereof) whether or not the Executive obtains other employment.

     14. Notice. All notices, requests, demands and other communications (collectively,
“Notices”) given or made pursuant to this Agreement shall be in writing and shall be deemed to have
been duly given or made as follows: (a) if sent by registered or certified mail in the United
States return receipt requested, postage and fees prepaid, two business days after mailing; (b) if
sent by reputable private air courier (such as DHL or Federal Express), two business days after
mailing; (c) if sent by facsimile transmission, with a copy mailed on the same day in the manner
provided in (a) or (b) above, when transmitted and receipt is confirmed by telephone; or (d) if
otherwise actually personally delivered, when delivered. All Notices shall be delivered to the
following addresses:

11

 

	 	 	 

	If to the Company:

	 	Franklin Savings and Loan Company
	 

	 	4750 Ashwood Drive, Cincinnati, Ohio 45241
	 

	 	Cincinnati, OH 45202
	 

	 	Attn: Corporate Secretary
	 
	 	 
	If to the Executive:

	 	John J. Kuntz
	 

	 	6911 Cozaddale Road
	 

	 	Goshen, OH 45122

     15. Modification. This Agreement may be amended, modified, superseded, cancelled,
renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by the parties hereto.

     16. Waiver. No delay on the part of any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any
party of any right, power or privilege hereunder, or any single or partial exercise of any right,
power or privilege hereunder, preclude any other or further exercise thereof or the exercise of any
other right, power or privilege hereunder.

     17. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Ohio, without regard to principles of conflict of laws.

     18. Assignment.

          (a) This Agreement shall be binding upon and shall inure to the benefit of the Company, and
its successors and assigns. The term “Company” as used herein shall include such successors and
assigns. The term “successors and assigns” as used herein shall mean a corporation or other entity
acquiring all or substantially all the assets and business of the Company (including this
Agreement) whether by operation of law or otherwise.

          (b) Neither this Agreement nor any rights or interest hereunder shall be assignable or
transferable by the Executive, the Executive’s beneficiaries or Personal Representatives, except
by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of
and be enforceable by the Executive’s Personal Representative.

     19. Fees and Expenses. From and after the Effective Date, the Company shall pay all
legal fees and related expenses (including the costs of experts, evidence and counsel) reasonably
incurred by the Executive as they become due as a result of a judgment obtained in favor of
Executive from a court of competent jurisdiction regarding: (i) the Executive’s termination of
employment (including all such fees and expenses, if any, incurred in contesting or disputing any
such termination of employment, (ii) the Executive’s seeking to obtain or enforce any right or
benefit provided by this Agreement or by any other plan or arrangement maintained by the Company
under which the Executive is or may be entitled to receive benefits. Such legal fees and expenses
shall include those fees and expenses incurred as a result of Executive’s hearing before the Board
as contemplated in Paragraph 11(c) of this Agreement.

12

 

     20. Severability. If any provision of this Agreement or any part thereof is
determined to be unenforceable, invalid or illegal, the validity of any other provision, or part
thereof shall not be affected adversely and this Agreement shall continue to be binding on the
parties hereto as if said unenforceable, invalid or illegal provisions or parts thereof had not
been included herein.

     21. Entire Agreement. This Agreement constitutes the entire agreement between the
parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral
or written, between the parties hereto with respect to the subject matter hereof.

     22. Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original but all of which together shall constitute one and the same
instrument.

     23. Headings. The headings in this Agreement are for reference purposes only and
shall not in any way affect the meaning or interpretation of this Agreement.

     24. Code Section 409A.

          (a) Notwithstanding anything to the contrary in this Agreement, no Deferred Compensation
Separation Benefits (as defined below) will become payable under this Agreement until Executive has
a “separation from service” within the meaning of Section 409A of the Code, and any proposed or
final regulations and guidance promulgated thereunder (“Section 409A”). Further, if Executive is a
“specified employee” within the meaning of Section 409A at the time of Executive’s termination
(other than due to death) and the severance payable to Executive, if any, pursuant to this
Agreement, when considered together with any other severance payments or separation benefits, are
considered deferred compensation under Section 409A (together, the “Deferred Compensation
Separation Benefits”), such Deferred Compensation Separation Payments that are otherwise payable
within the first six (6) months following Executive’s termination of employment will become payable
on the first payroll date that occurs on or after the date six (6) months and one (1) day following
the date of Executive’s termination of employment. All subsequent Deferred Compensation
Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to
each payment o benefit. Notwithstanding anything herein to the contrary, if Executive dies
following his termination but prior to the six (6) month anniversary of his termination, then any
payments delayed in accordance with this paragraph will be payable in a lump sum as soon as
administratively practicable after the date of Executive’s death and all other Deferred
Compensation Separation Benefits will be payable in accordance with the payment schedule applicable
to each payment or benefit. Each payment and benefit payable under this Agreement is intended to
constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

          (b) Any amount paid under this Agreement that satisfies the requirements of the “short-term
deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations shall not constitute
Deferred Compensation Separation Benefits for purposes of Section 24(a) above.

          (c) Any amount paid under this Agreement that qualifies as a payment made as a result of an
involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the

13

 

Treasury regulations that does not exceed the Section 409A Limit (as defined below) shall not constitute
Deferred Compensation Separation Benefits for purposes of Section 24(a) above. For purposes of
this Section 24(c), the “Section 409A Limit” will mean the lesser of two (2) times: (i) Executive’s
annualized compensation based upon the annual rate of pay paid to Executive during the Company’s
taxable year preceding the Company’s taxable year of Executive’s termination of employment as
determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1); or (ii) the maximum amount that may
be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the
year in which Executive’s employment is terminated.

          (d) The foregoing provisions are intended to comply with the requirements of Section 409A so
that none of the severance payments and benefits to be provided hereunder will be subject to the
additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so
comply. The Company and Executive agree to work together in good faith to consider amendments to
this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to
avoid imposition of any additional tax or income recognition prior to actual payment to executive
under Section 409A.

          (e) Any reimbursements or in-kind benefits provided under the Agreement shall be made or
provided in accordance with the requirements of Section 409A of the Code, including, where
applicable, the requirement that (a) any reimbursement is for expenses incurred during the period
of time specified in the Agreement, (b) the amount of expenses eligible for reimbursement, or
in-kind benefits provided, during a calendar year may not affect the expenses eligible for
reimbursement, or in-kind benefits to be provided, in any other calendar year, (c) the
reimbursement of an eligible expense will be made no later than the last day of the calendar year
following the year in which the expense is incurred, and (d) the right to reimbursement or in-kind
benefits is not subject to liquidation or exchange for another benefit.”

          (f) Nothing herein shall be construed as the guarantee of any particular tax treatment to the
Executive, and none of the Company, its Board of Directors, or any of its affiliates shall have any
liability to the Executive with respect to any failure to comply with the requirements of Section
409A of the Code.

[Signature Page Follows]

14

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 

	FRANKLIN SAVINGS AND LOAN COMPANY	 	 	 	EXECUTIVE
	 
	By:

	 	/s/ Gretchen Schmidt
	 	 	 	/s/ John J. Kuntz
	 

	 	 
	 	 	 	 
	 

	 	Gretchen Schmidt, President
	 	 	 	John J. Kuntz

15

 

EXHIBIT A

GENERAL RELEASE

     I, John J. Kuntz, in consideration of the material obligations of Franklin Savings and Loan
Company (the “Company”) under the Employment Agreement, dated as of April 1, 2010 (the “Employment
Agreement”) do hereby release and forever discharge as of the date hereof the Company and all of
its present and former shareholders, directors, officers, agents, representatives, employees,
subsidiaries, affiliates, successors and assigns (collectively, the “Released Parties”) to the
extent provided below.

     1. I understand that the payments and benefits to be paid and provided to me under Paragraph 8
of the Employment Agreement represent, in part, consideration for signing this General Release and
are not salary, wages, benefits or payments to which I was already entitled. I understand and agree
that I will not receive the payments and benefits specified in Paragraph 8 of the Employment
Agreement (other than for any unpaid compensation, benefits and expenses to which I am entitled
for employment prior to termination) unless I execute this General Release and do not revoke this
General Release within the time period permitted hereafter or breach this General Release.

     2. Except as provided in Paragraphs 4 and 11 below, I knowingly and voluntarily release and
forever discharge the Company and the other Released Parties from any and all claims,
controversies, actions, causes of action, cross-claims, counter-claims, demands, debts,
compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for
costs and attorneys’ fees, or liabilities of any nature whatsoever in law and in equity, both past
and present (through the date of this General Release) and whether known or unknown, suspected, or
claimed against the Company or any of the Released Parties which I, my spouse, or any of my heirs,
executors, administrators or assigns, may have, which arise out of or are connected with my
employment with, or my separation from, the Company (including, but not limited to, any allegation,
claim or violation, arising under: Title VII of the Civil Rights Act of 1964, as amended; the Civil
Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the
Older Workers Benefit Protection Act); the Equal Pay Act of 1963, as amended; the Americans with
Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the Civil Rights Act of 1866,
as amended; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income
Security Act of 1974; any applicable Executive Order Programs; the Fair Labor Standards Act; or
their state or local counterparts; or under any other federal, state or local civil or human rights
law, or under any other local, state, or federal law, regulation or ordinance; or under any public
policy, contract or tort, or under common law; or arising under any policies, practices or
procedures of the Company; or any claim for wrongful discharge, breach of contract, infliction of
emotional distress, defamation; or any claim for costs, fees, or other expenses, including
attorneys’ fees incurred in these matters) (all of the foregoing collectively referred to herein as
the “Claims”).

     3. I represent that I have made no assignment or transfer of any Claims or other matters
covered by Paragraph 2 above.

 

 

     4. I agree that this General Release does not waive or release any rights or claims that I may
have under the Age Discrimination in Employment Act of 1967 which arise after the date I execute
this General Release. I acknowledge and agree that my separation from employment with the Company
in compliance with the terms of the Employment Agreement shall not serve as the basis for any
Claim, including, without limitation, any Claim under the Age Discrimination in Employment Act of
1967.

     5. In signing this General Release, I acknowledge and intend that it shall be effective as a
bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that
this General Release shall be given full force and effect according to each and all of its express
terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding
any state statute that expressly limits the effectiveness of a general release of unknown,
unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims
hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential and
material term of this General Release and that without such waiver the Company would not have
agreed to the terms of the Employment Agreement. I further agree that in the event I should bring
a Claim seeking damages against the Company, or in the event I should seek to recover against the
Company in any Claim brought by a governmental agency on my behalf, this General Release shall
serve as a complete defense to such Claims. I further agree that I am not aware of any pending
charge or complaint of the type described in Paragraph 2 as of the execution of this General
Release.

     6. I agree that neither this General Release, nor the furnishing of the consideration for this
General Release, shall be deemed or construed at any time to be an admission by the Company, any
Released Party or myself of any improper or unlawful conduct.

     7. I agree that I will forfeit all cash amounts payable by the Company pursuant to Paragraph 8
of the Employment Agreement if I challenge the validity of this General Release. I also agree that
if I violate this General Release by suing the Company or the other Released Parties, I will pay
all costs and expenses of defending against the suit incurred by the Released Parties, including
reasonable attorneys’ fees, and will return all payments received by me pursuant to Paragraph 8 of
the Employment Agreement.

     8. I agree that this General Release is confidential and agree not to disclose any information
regarding the terms of this General Release, except to my immediate family and any tax, legal or
other counsel I have consulted regarding the meaning or effect hereof or as required by law, and I
will instruct each of the foregoing not to disclose the same to anyone.

     9. Any non-disclosure provision in this General Release does not prohibit or restrict me (or
my attorney) from responding to any inquiry about this General Release or its underlying facts and
circumstances by any governmental entity.

     10. I agree to reasonably cooperate with the Company in any internal investigation or
administrative, regulatory, or judicial proceeding. I understand and agree that my cooperation may

17

 

include, but not be limited to, making myself available to the Company upon reasonable notice for
interviews and factual investigations; appearing at the Company’s request to give testimony
without requiring service of a subpoena or other legal process; volunteering to the Company
pertinent information; and turning over to the Company all relevant documents which are or may come
into my possession all at times and on schedules that are reasonably consistent with my other
permitted activities and commitments. I understand that in the event the Company asks for my
cooperation in accordance with this provision, the Company will reimburse me solely for reasonable
travel expenses, including lodging and meals, upon my submission of receipts.

     11. Notwithstanding anything in this General Release to the contrary, this General Release
shall not relinquish, diminish, or in any way affect any rights or claims arising out of any breach
by the Company or any Released Party of the Employment Agreement after the effective date of this
Release.

     12. Whenever possible, each provision of this General Release shall be interpreted in, such
manner as to be effective and valid under applicable law, but if any provision of this General
Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any
other provision or any other jurisdiction, but this General Release shall be reformed, construed
and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never
been contained herein.

BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT:

	(a)	 	I HAVE READ IT CAREFULLY;

	(b)	 	I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT
NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED;
TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963; THE
AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF
1974, AS AMENDED;

	(c)	 	I VOLUNTARILY CONSENT TO EVERYTHING IN IT;

	(d)	 	I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR,
AFTER CAREFUL READING AND CONSIDERATION I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION;

	(e)	 	I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE SUBSTANTIALLY IN ITS
FINAL FORM ON                  
               
                      ,                     TO CONSIDER IT [AND THE CHANGES MADE SINCE THE
                
                
                 
     ,            
         VERSION OF THIS RELEASE ARE NOT MATERIAL AND WILL NOT RESTART THE
REQUIRED 21-DAY PERIOD;]

18

 

	(f)	 	[THE CHANGES TO THE AGREEMENT SINCE                                                       ,                    
 EITHER
ARE NOT MATERIAL OR WERE MADE AT MY REQUEST.]

	(g)	 	I UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT
THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS
EXPIRED; AND

	(h)	 	I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR
MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE
COMPANY AND BY ME.

	 	 	 

	DATE:                                                       ,             

	 	                                                                                

19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]